CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
acitretindrug
Likely dose
Acitretin 25 mg orally once dailyAI-extracted
Key inclusion· 4
  • ✓Age 18 to 80 years
  • ✓Moderate to severe psoriasis with physician global assessment ≥3
  • ✓Currently on etanercept 50 mg SQ once weekly
  • ✓Failed to achieve PASI 75 after ≥12 weeks of etanercept monotherapy
Key exclusion· 5
  • ✕Women of childbearing potential
  • ✕Uncontrolled hypertriglyceridemia
  • ✕Severely impaired hepatic function
  • ✕Epilepsy or multiple sclerosis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00156247
NCT00156247Phase 2Completed
CompareCT.gov

Pilot, Single-Arm Study of the Effect of Adding Acitretin to Etanercept Therapy in Patients With Moderate to Severe Psoriasis Who Fail to Respond to Etanercept Monotherapy

University of Medicine and Dentistry of New Jersey·interventional·Posted Sep 12, 2005·Updated Feb 16, 2015

In Brief

A Phase 2 clinical trial evaluating acitretin for Psoriasis. Completed, enrolled 10 participants.

Detailed Summary

To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsConnetics Corp.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartSep 1, 2005
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 20.8 years ago

Interventions

acitretindrug

Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.